Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
IPO Year: 2014
Exchange: NASDAQ
Website: eagleus.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/10/2023 | $26.00 → $17.00 | Neutral → Underweight | Piper Sandler |
8/9/2023 | $26.00 → $17.00 | Neutral → Underweight | Piper Sandler |
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
NT 10-Q - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
NT 10-Q - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
8-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
NT 10-K - EAGLE PHARMACEUTICALS, INC. (0000827871) (Filer)
Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously
Piper Sandler downgraded Eagle Pharma from Neutral to Underweight and set a new price target of $17.00 from $26.00 previously
RBC Capital Mkts resumed coverage of Eagle Pharma with a rating of Outperform and set a new price target of $52.00
WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b
WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTimeToll free (U.S.)InternationalThursday, November 9, 2023 8:30 a.m. ET800-343-4136203-518-9843 Webcast (live and replay)www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for two weeks after the ca
• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income1 was $1.18 per basic and diluted share • Q2 2023 net income was $5.2 million • Q2 2023 adjusted non-GAAP EBITDA1 was $20.7 million • Gross margin was 74% for the first half of 2023, up from 73% for the first half of 2022 • Adjusted non-GAAP gross margin1 was 83% for the first half of 2023, up from 74% for the first half of 2022 • Gross profit in its oncology business was $41.9 million in the second quarter of 2023 compared with $38.7 million in the prior year period, representing gross margin of 80% and 72%, respectively • Adjusted non-GAAP gross pr
WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTuesday, August 8, 2023Time8:30 a.m. ETToll free (U.S.)800-343-4136International203-518-9814 Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for two weeks after the call's comp
Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income1 was $1.27 per basic and $1.26 per diluted shareQ1 2023 adjusted non-GAAP EBITDA of $22.3 millionQ1 2023 net sales of PEMFEXY® totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial (non-340B) pemetrexed market for the second quarter of 2023 to date2BENDEKA®3 and BELRAPZO®4 - both ready-to-dilute ("RTD") products — combined maintained approximately 89% share of the bendamustine U.S. market for the first quarter of 2023 compared to approximately 90% historically5Company reaffirms full year
WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Tuesday, May 9, 2023Time 8:30 a.m. ETToll free (U.S.) 800-274-8461International 203-518-9814 Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for two weeks after the call's completion
• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share1 • FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 • FY 2022 net sales of PEMFEXY® totaled $67.5 million, and were $12.1 million in Q4 2022, representing a 6% U.S. market share in community oncology at the end of Q4 2022; already captured a 10% share through February 2023; anticipate e
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date: Monday, March 13, 2023 Time: 8:30 a.m. ET Toll free (U.S.) 800-445-7795 International 785-424-1789 Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for tw
WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line items in the financial statements included therein and corresponding references to such items in the narrative disclosure as described in the Company's Form 8-K/A filed on November 9, 2022. All other information in the earnings press release remains unchanged, including adjusted non-GAAP net income, adjusted non-GAAP basic and diluted earnings per share and adjusted non-GAAP EBITDA. The corrected
Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share1Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted shareNine-month 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $6.69 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company's historyNine-month 2022 revenue of $255.9 million exceeds full year 2021 revenue of $171.5 millionNine-month 2022 net sales of vasopressin and PEMFEXY combined totaled $114.9 millionBENDEKA®2 and BELRAP
SC 13G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13D - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
SC 13G/A - EAGLE PHARMACEUTICALS, INC. (0000827871) (Subject)
-SEC Filing
Gainers IGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 21.96% to $1.05. The company's market cap stands at $153.8 million. MultiPlan (NYSE:MPLN) shares rose 18.57% to $0.64. The company's market cap stands at $415.4 million. Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 14.61% to $2.98. The company's market cap stands at $7.4 million. TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 12.79% to $1.41. The company's market cap stands at $9.3 million. Indaptus Therapeutics (NASDAQ:INDP) shares moved upward
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024, in Savannah, Georgia. "Evaluating nausea in children remains a challenging and complex process," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "We are therefore pleased to have this opportunity to share the detail
United States Court Of Appeals For The Federal Circuit Affirmed The Previously Announced Decision By The United States District Court For The District Of Delaware Finding That Drug Applications Referencing Eagle Pharmaceuticals' Belrapzo (Bendamustine) Filed By Slayback Pharma And Apotex Did Not Infringe Eagle's Previously Issued ‘483 Patent
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue treatment of postoperative nausea and vomiting ("PONV") despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV ---- In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2,3 ---- This post-hoc analysis of pivotal trials demonstrates that Barhemsys provides statistically significant (p=0.006) nausea relief in patients with established PONV ---- A single 10 mg dose of intravenous amisulpride significantly reduc
Gainers Altimmune (NASDAQ:ALT) shares increased by 45.2% to $4.59 during Thursday's after-market session. The company's market cap stands at $246.6 million. NovaBay Pharmaceuticals (AMEX:NBY) stock increased by 9.89% to $0.33. The market value of their outstanding shares is at $2.1 million. China Pharma Holding (AMEX:CPHI) shares rose 9.63% to $0.12. The market value of their outstanding shares is at $3.9 million. NeuBase Therapeutics (NASDAQ:NBSE) stock moved upwards by 9.48% to $1.08. The company's market cap stands at $4.0 million. Minerva Surgical (NASDAQ:UTRS) stock increased by 8.1% to $2.0. The market value of their outstanding shares is at $17.7 million. Akanda (NASDAQ:AKAN) st
WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (the "Company" or "Eagle") today announced that it received a notice (the "Notice") on August 21, 2024, from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the "Q2 2024 Form 10-Q") serves as an additional and separate basis for delisting. As previously disclosed, on August 1, 2024, the Company received a notice from Nasdaq indicating that following the Company's previousl
WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (the "Company" or "Eagle") today announced that it received a notice (the "Notice") on May 20, 2024, from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it has initiated a process to delist the Company's securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 (the "Q3 2023 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K") by May 13, 2024. The Notice further advises the Company that, pursuant to Nasdaq Listing Rule 5810(d)(2), th
WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024, in Savannah, Georgia. "Evaluating nausea in children remains a challenging and complex process," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "We ar
WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that data from the Company's Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting ("PONV") will be presented at the upcoming American Society of PeriAnesthesia Nurses (ASPAN) 2024 National Conference, which is being held April 14-18, 2024, in Orlando, Florida. The data being presented relate to a prespecified pharmacokinetic ("PK") subset of patients from a Phase III, randomized, multicenter, double-blind, placebo-controlled, parallel-group study in adult surgic
WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (the "Company") today announced that it received a notice (the "Notice") on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the
WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today provided an update on its bendamustine intellectual property portfolio. On January 16, 2024, the United States Court of Appeals for the Federal Circuit affirmed the previously announced decision by the United States District Court for the District of Delaware finding that the 505(b)(2) drug applications referencing BELRAPZO® filed by Slayback Pharma Limited Liability Company ("Slayback")1 and Apotex Inc. and Apotex Corp. ("Apotex") did not infringe Eagle's previously issued ‘483 patent. Slayback, Apotex, and Baxter Healthcare Corporation ("Baxter") launche
-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue treatment of postoperative nausea and vomiting ("PONV") despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV -- -- In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2,3 -- -- This post-hoc analysis of pivotal trials demonstrates that Barhemsys provides statistically significant (p=0.006) nausea relief in patients with established PONV -- -- A single 10 mg dose of intravenous amisulpride signifi
WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (the "Company") today announced that it received a notice (the "Notice") on November 27, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it is not currently in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the "SEC"), as a result of the Company's failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 1
– CEO and Founder Scott Tarriff Retires – – Chairman Michael Graves to Serve as Interim Executive Chairman – WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced a change in management. Effective immediately Scott Tarriff, Founder, President and Chief Executive Officer of the Company, has announced his resignation and retirement from his positions with the Company as President, Chief Executive Officer and Director on the Company's Board of Directors. Michael Graves, Eagle Pharmaceuticals' Chairman of the Board, has assumed the role of Interim Executive Chairman of the Board to lead the managem
WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
4 - EAGLE PHARMACEUTICALS, INC. (0000827871) (Issuer)
WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. "We are very pleased with our acquisition of Acacia Pharma Group Plc ("Acacia") and its two commercial products, BARHEMSYS® and BYFAVO®. As we commenced their integration, we continued to be impressed with Acacia Pharma's previous plans and positioning of the products. It is our belief that the two products were underinvested, both from a cost and manpower perspective. Additionally, the products were launched into a very difficult COVID environment, in which access to d
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Luciana ("Lu") Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration ("FDA" or "Agency"). "We are delighted to welcome Lu to the Eagle Board of Directors. Lu is deeply committed to public health, having served in prominent roles at FDA and the National Security Council. Lu has spent her career at the forefront of U.S. healthcare policy, addressing some of the world's most complex challenges. Her